Detection of subclinical atrial fibrillation after cryptogenic stroke using implantable cardiac monitors.


Journal

European journal of internal medicine
ISSN: 1879-0828
Titre abrégé: Eur J Intern Med
Pays: Netherlands
ID NLM: 9003220

Informations de publication

Date de publication:
10 2021
Historique:
received: 01 02 2021
revised: 17 06 2021
accepted: 20 06 2021
pubmed: 13 7 2021
medline: 21 10 2021
entrez: 12 7 2021
Statut: ppublish

Résumé

Implantable cardiac monitor (ICM) revealed subclinical atrial fibrillation (SCAF) in up to 30% of cryptogenic stroke (CS) patients in randomized trials. However, real world data are limited. We investigated SCAF occurrence, treatments, clinical outcomes and predictors of SCAF in a multicenter real-world population subjected to ICM after CS. From September 2016 to November 2019, 20 Italian centers collected data of consecutive patients receiving ICM after CS and followed with remote and outpatient follow-up according to clinical practice. All device-detected AF events were confirmed by the cardiologist to diagnose SCAF. ICM was implanted in 334 CS patients (mean age±SD 67.4±11.5 years, 129 (38.6%) females, 242 (76.1%) with CHA In a real-world population, ICM detected SCAF in more than a quarter of CS patients. This experience confirms the relevance of implanting CS patients, for maximizing the possibilities to detect AF, following failure of Holter monitoring, according to guidelines. However, there is need to demonstrate that shift to oral anticoagulation following SCAF detection is associated with reduced risk of recurrent stroke.

Sections du résumé

BACKGROUND
Implantable cardiac monitor (ICM) revealed subclinical atrial fibrillation (SCAF) in up to 30% of cryptogenic stroke (CS) patients in randomized trials. However, real world data are limited.
OBJECTIVES
We investigated SCAF occurrence, treatments, clinical outcomes and predictors of SCAF in a multicenter real-world population subjected to ICM after CS.
METHODS
From September 2016 to November 2019, 20 Italian centers collected data of consecutive patients receiving ICM after CS and followed with remote and outpatient follow-up according to clinical practice. All device-detected AF events were confirmed by the cardiologist to diagnose SCAF.
RESULTS
ICM was implanted in 334 CS patients (mean age±SD 67.4±11.5 years, 129 (38.6%) females, 242 (76.1%) with CHA
CONCLUSIONS
In a real-world population, ICM detected SCAF in more than a quarter of CS patients. This experience confirms the relevance of implanting CS patients, for maximizing the possibilities to detect AF, following failure of Holter monitoring, according to guidelines. However, there is need to demonstrate that shift to oral anticoagulation following SCAF detection is associated with reduced risk of recurrent stroke.

Identifiants

pubmed: 34247889
pii: S0953-6205(21)00233-8
doi: 10.1016/j.ejim.2021.06.022
pii:
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-93

Informations de copyright

Copyright © 2021. Published by Elsevier B.V.

Auteurs

Andrea Ungar (A)

Division of Geriatric and Intensive Care Medicine, Syncope Unit, University of Florence, Firenze, Italy. Electronic address: andrea.ungar@unifi.it.

Francesca Pescini (F)

Stroke Unit Emergency Department, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy.

Martina Rafanelli (M)

Division of Geriatric and Intensive Care Medicine, Syncope Unit, University of Florence, Firenze, Italy.

Maria Vittoria De Angelis (MV)

Neurology Department, SS. Annunziata Hospital, Chieti, Italy.

Massimiliano Faustino (M)

Aritmology Department, SS. Annunziata Hospital, Chieti, Italy.

Caterina Tomaselli (C)

Cardiology Department, Annunziata Hospital, Cosenza, Italy.

Alfredo Petrone (A)

Neurology Department, Annunziata Hospital, Cosenza, Italy.

Giovanni Forleo (G)

Cardiology Unit, Luigi Sacco Hospital, Milan, Italy.

Giovanni Morani (G)

Division of Cardiology, Department of Medicine, University of Verona, Verona, Italy.

Stefano Forlivesi (S)

Neurology and Stroke Unit, Department of Neuroscience, Azienda Ospedaliera Universitaria Integrata, Verona, Italy.

Giulio Molon (G)

Cardiology Department, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy.

Alessandro Adami (A)

Stroke Center, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Italy.

Massimiliano Maines (M)

Cardiology Department, S. Maria del Carmine Hospital, Rovereto, Italy.

Chiara Stegagno (C)

Neurology Department, S. Maria del Carmine Hospital, Rovereto, Italy.

Anna Poggesi (A)

Stroke Unit Emergency Department, Azienda Ospedaliero Universitaria Careggi, Firenze, Italy; IRCCS Fondazione Don Carlo Gnocchi, Firenze, Italy; NEUROFARBA Department, University of Florence, Firenze, Italy.

Leonardo Pantoni (L)

"Luigi Sacco" Department of Biomedical and Clinical Sciences, University of Milan, Milano, Italy. Electronic address: leonardo.pantoni@unimi.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH